Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B known ✓ | Q07343 | 16/20 | 0.52 |
| ▸ | PDE4A known ✓ | P27815 | 15/20 | 0.52 |
| ▸ | PDE4C known ✓ | Q08493 | 15/20 | 0.52 |
| ▸ | PDE4D known ✓ | Q08499 | 15/20 | 0.52 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15252405 | 0.99 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DTP53 | |
| SCHEMBL3553865 | 0.89 | PDE4B (0.55) | PDE4BPDE4APDE4CPDE4DTP53 | |
| SCHEMBL3554030 | 0.89 | PDE4B (0.59) | PDE4BPDE4APDE4CPDE4DTP53 | |
| SCHEMBL1829132 | 0.88 | PDE4A (0.54) | PDE4BPDE4APDE4CPDE4DTP53 | |
| SCHEMBL1823551 | 0.88 | PDE4A (0.49) | PDE4BPDE4APDE4CPDE4DTP53 | |
| SCHEMBL3550822 | 0.87 | PDE4B (0.60) | PDE4BPDE4APDE4CPDE4DTP53 | |
| SCHEMBL1824931 | 0.86 | PDE4A (0.52) | PDE4BPDE4APDE4CPDE4DTP53 | |
| SCHEMBL537176 | 0.86 | PDE4A (0.52) | PDE4BPDE4APDE4CPDE4DTP53 | |
| SCHEMBL3559689 | 0.85 | PDE4B (0.51) | PDE4BPDE4APDE4CPDE4DTP53 | |
| SCHEMBL15869360 | 0.85 | PDE4B (0.69) | PDE4BPDE4APDE4CPDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1605896-B1 | 7-AMINO- ISOINDOLYL COMPOUNDS AMD THEIR PHARMACEUTICAL USES | CELGENE CORP (US) | 2013-09-18 | — | — | EP | claimed |
| US-7034052-B2 | 7-Amido-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| US-20040254214-A1 | 7-Amido-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION | 2004-12-16 | — | — | US | claimed |
| EP-1605896-B1 | 7-AMINO- ISOINDOLYL COMPOUNDS AMD THEIR PHARMACEUTICAL USES | CELGENE CORP (US) | 2013-09-18 | — | — | EP | disclosed |
| US-7799819-B2 | 7-Amido-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090131505-A1 | 7-Amido-isoindolyl Compounds and Their Pharmaceutical Uses | MAN HON-WAH | 2009-05-21 | — | — | US | disclosed |
| US-7511072-B2 | 7-amido-isoindolyl compounds and methods of its use | CELGENE CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-20070254942-A1 | 7-amido-isoindolyl compounds and methods of its use | CELGENE CORPORATION. | 2007-11-01 | — | — | US | disclosed |
| US-7256210-B2 | 7-amido-isoindolyl compounds and methods of their use | CELGENE CORPORATION (US) | 2007-08-14 | — | — | US | disclosed |
| US-7034052-B2 | 7-Amido-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| US-20060058362-A1 | 7-Amido-isoindolyl compounds and methods of their use | MAN HON-WAH | 2006-03-16 | — | — | US | disclosed |
| EP-1605896-A2 | 7-AMINO- ISOINDOLYL COMPOUNDS AMD THEIR PHARMACEUTICAL USES | CELGENE CORPORATION (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20040254214-A1 | 7-Amido-isoindolyl compounds and their pharmaceutical uses | CELGENE CORPORATION | 2004-12-16 | — | — | US | disclosed |
| WO-2004080423-A2 | 7-AMINO- ISOINDOLYL COMPOUNDS AMD THEIR PHARMACEUTICAL USES | CELGENE CORPORATION (US) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058362-A1 | 7-Amido-isoindolyl compounds and methods of their use | MCL1, APC, HPGDS | PDE4B 2106/4885PDE4A 1516/4885PDE4C 1281/4885 |
| US-20040254214-A1 | 7-Amido-isoindolyl compounds and their pharmaceutical uses | MCL1, APC, THPO | PDE4B 729/4885PDE4A 445/4885PDE4C 403/4885 |
| US-20090131505-A1 | 7-Amido-isoindolyl Compounds and Their Pharmaceutical Uses | THPO, MCL1, HPGDS | PDE4B 564/4885PDE4A 576/4885PDE4C 874/4885 |
| US-20070254942-A1 | 7-amido-isoindolyl compounds and methods of its use | MCL1, THPO, APC | PDE4B 1964/4885PDE4A 2086/4885PDE4C 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.